PortfoliosLab logo
SHEL vs. VRTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SHEL and VRTX is 0.53, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Performance

SHEL vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Shell plc (SHEL) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

SHEL:

-0.30

VRTX:

0.14

Sortino Ratio

SHEL:

-0.13

VRTX:

0.40

Omega Ratio

SHEL:

0.98

VRTX:

1.06

Calmar Ratio

SHEL:

-0.26

VRTX:

0.21

Martin Ratio

SHEL:

-0.61

VRTX:

0.55

Ulcer Index

SHEL:

7.92%

VRTX:

8.86%

Daily Std Dev

SHEL:

23.01%

VRTX:

28.41%

Max Drawdown

SHEL:

-67.46%

VRTX:

-91.77%

Current Drawdown

SHEL:

-9.43%

VRTX:

-14.97%

Fundamentals

Market Cap

SHEL:

$197.06B

VRTX:

$112.83B

EPS

SHEL:

$4.38

VRTX:

-$3.82

PEG Ratio

SHEL:

1.46

VRTX:

2.53

PS Ratio

SHEL:

0.70

VRTX:

10.17

PB Ratio

SHEL:

1.10

VRTX:

6.62

Total Revenue (TTM)

SHEL:

$281.07B

VRTX:

$11.09B

Gross Profit (TTM)

SHEL:

$42.59B

VRTX:

$9.54B

EBITDA (TTM)

SHEL:

$54.83B

VRTX:

-$228.00M

Returns By Period

In the year-to-date period, SHEL achieves a 7.09% return, which is significantly lower than VRTX's 9.11% return. Over the past 10 years, SHEL has underperformed VRTX with an annualized return of 5.37%, while VRTX has yielded a comparatively higher 13.33% annualized return.


SHEL

YTD

7.09%

1M

6.91%

6M

1.44%

1Y

-6.74%

5Y*

21.17%

10Y*

5.37%

VRTX

YTD

9.11%

1M

-9.26%

6M

-12.43%

1Y

3.92%

5Y*

9.70%

10Y*

13.33%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SHEL vs. VRTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SHEL
The Risk-Adjusted Performance Rank of SHEL is 3333
Overall Rank
The Sharpe Ratio Rank of SHEL is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of SHEL is 3131
Sortino Ratio Rank
The Omega Ratio Rank of SHEL is 3131
Omega Ratio Rank
The Calmar Ratio Rank of SHEL is 3333
Calmar Ratio Rank
The Martin Ratio Rank of SHEL is 3636
Martin Ratio Rank

VRTX
The Risk-Adjusted Performance Rank of VRTX is 5454
Overall Rank
The Sharpe Ratio Rank of VRTX is 5757
Sharpe Ratio Rank
The Sortino Ratio Rank of VRTX is 4747
Sortino Ratio Rank
The Omega Ratio Rank of VRTX is 4949
Omega Ratio Rank
The Calmar Ratio Rank of VRTX is 6161
Calmar Ratio Rank
The Martin Ratio Rank of VRTX is 5858
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SHEL vs. VRTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Shell plc (SHEL) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current SHEL Sharpe Ratio is -0.30, which is lower than the VRTX Sharpe Ratio of 0.14. The chart below compares the historical Sharpe Ratios of SHEL and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

SHEL vs. VRTX - Dividend Comparison

SHEL's dividend yield for the trailing twelve months is around 4.19%, while VRTX has not paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
SHEL
Shell plc
4.19%4.39%3.76%3.48%3.78%5.44%6.14%5.48%4.79%5.88%6.98%4.72%
VRTX
Vertex Pharmaceuticals Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

SHEL vs. VRTX - Drawdown Comparison

The maximum SHEL drawdown since its inception was -67.46%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for SHEL and VRTX. For additional features, visit the drawdowns tool.


Loading data...

Volatility

SHEL vs. VRTX - Volatility Comparison

The current volatility for Shell plc (SHEL) is 6.46%, while Vertex Pharmaceuticals Incorporated (VRTX) has a volatility of 13.54%. This indicates that SHEL experiences smaller price fluctuations and is considered to be less risky than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

SHEL vs. VRTX - Financials Comparison

This section allows you to compare key financial metrics between Shell plc and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20212022202320242025
69.23B
2.77B
(SHEL) Total Revenue
(VRTX) Total Revenue
Values in USD except per share items

SHEL vs. VRTX - Profitability Comparison

The chart below illustrates the profitability comparison between Shell plc and Vertex Pharmaceuticals Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%100.0%20212022202320242025
18.4%
86.9%
(SHEL) Gross Margin
(VRTX) Gross Margin
SHEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Shell plc reported a gross profit of 12.71B and revenue of 69.23B. Therefore, the gross margin over that period was 18.4%.

VRTX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.

SHEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Shell plc reported an operating income of 9.47B and revenue of 69.23B, resulting in an operating margin of 13.7%.

VRTX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.

SHEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Shell plc reported a net income of 4.78B and revenue of 69.23B, resulting in a net margin of 6.9%.

VRTX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.